Skip to content
Search

Latest Stories

Haleon invests over £43mn to upgrade its Richmond R&D facility

Haleon upgrading its Richmond facility to boost R&D Capabilities
Haleon Richmond Rd. facility upgrade

Haleon’s Weybridge site in the UK is set to open a global oral health innovation centre in 2027

Haleon is enhancing its research and development (R&D) capabilities and accelerating its new product innovation pipeline with a $54 million (£43.49 million) investment in its global R&D centre of excellence in Richmond, Virginia, USA.

This investment is in addition to the company’s annual R&D budget of approximately £300 million.


The Richmond site, one of Haleon’s three global R&D centres of excellence, alongside facilities in Weybridge, UK, and Suzhou, China, provides the global scale necessary for the company to deliver disruptive and locally relevant brand innovations across over 170 markets worldwide.

The upgraded facility will feature new, state-of-the-art laboratories designed to enable development of innovations across ingredients, formulations, flavours, formats and packaging for Haleon’s Over-the-Counter (OTC) and Vitamins, Minerals and Supplements (VMS) categories.

Franck Riot, Haleon’s chief R&D officer, emphasised the critical role of R&D in the company’s success, stating, “R&D is the cornerstone of our business and the innovation engine behind our category-leading brands.”

“Consumers trust our products because they trust our science - so investing in R&D is vital for driving consumer preference for our brands.”

Riot noted that this significant investment will further expand their R&D and innovation capabilities, allowing them to deliver better everyday health to millions of consumers globally.

In addition to this new investment, Haleon’s Weybridge site in the UK is set to open a global oral health innovation centre in 2027. The company announced a £130 million investment for the new centre in October 2024.

Richmond Image 2 Haleon’s global R&D centre of excellence in Richmond, US

The Richmond site, established in the 1960s, has evolved through various mergers and acquisitions. In recent years, the site has expanded its scope and increased its workforce by 100 team members since 2020.

Many of Haleon’s top brands, including Advil, Emergen-C, and Robitussin, have either been created or grown at the site.

Haleon’s critical technical functions are based at this site including consumer science, formulation development, process scale up, analytical test method development, microbiology, product stability, packaging design, and clinical supplies.

 

 

More For You

Pharmacy owners to receive 19p SAF increase in advance payments for April and May 2025

The Single Activity Fee (SAF) was increased by 19p to £1.46 per item, effective from April 2024.

gettyimages

19p SAF increase to be included in April and May 2025 advance payments

Following discussions with the Department of Health and Social Care (DHSC), Community Pharmacy England (CPE) has agreed a mechanism that will allow pharmacy owners to receive the 19p increase to the Single Activity Fee (SAF) earlier for the dispensing months of April and May 2025.

CPE said: “The advance payments for these dispensing months will be adjusted to incorporate the uplift to the SAF. No adjustment to advance payments will be required from the June 2025 dispensing month onwards.”

Keep ReadingShow less
CPE invites pharmacy owners to share their views on new CPCF funding settlement

What do you think should be the next priority for the Government?

gettyimages

Pharmacy owners asked to share their views on new CPCF arrangements

Community Pharmacy England (CPE) is urging pharmacy owners to share their views on the new Community Pharmacy Contractual Framework (CPCF) funding settlement ahead of its next full Committee meeting, scheduled for 30 April–1 May.

The Committee said it had agreed to the settlement "reluctantly," acknowledging that it represents a significant shift after years of real-terms funding cuts, while admitting that it’s “still not sufficient to match the continued scale of pressures facing pharmacy businesses.”

Keep ReadingShow less
Homecare medicines services face many challenges beyond pharmacy's control

Homecare medicines services face many challenges beyond pharmacy's control

gettyimages

GPhC calls for industry-wide collaboration to strengthen homecare medicines services

The General Pharmaceutical Council (GPhC) has called for industry-wide collaboration to improve homecare medicines services to ensure patients always receive their medicines when needed.

The call follows a recent review by the regulator, which identified several challenges facing homecare services, many of which were beyond the immediate control of the pharmacies providing them.

Keep ReadingShow less
Lack of funding deters NI pharmacy contractors from expanding portfolio

W G Hamilton Pharmacy is the third pharmacy in Northern Ireland to be recently sold to first-time buyers.

Pharmacy ownership trends shift in Northern Ireland due to funding gap

An increasing number of pharmacies in Northern Ireland are being acquired by first-time buyers, as existing contractors and groups pull back from expanding their portfolios amid ongoing funding pressures, according to specialist business property adviser Christie & Co.

Among the most recent sales is W G Hamilton Pharmacy, a busy community pharmacy in Ballysillan, North Belfast.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less